| Tertiary lymphoid structures improve immunotherapy and survival in melanoma R Cabrita, M Lauss, A Sanna, M Donia, M Skaarup Larsen, S Mitra, ... Nature 577 (7791), 561-565, 2020 | 1773 | 2020 |
| Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging LS Steelman, WH Chappell, SL Abrams, CR Kempf, J Long, P Laidler, ... Aging (Albany NY) 3 (3), 192, 2011 | 835 | 2011 |
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health WH Chappell, LS Steelman, JM Long, RC Kempf, SL Abrams, RA Franklin, ... Oncotarget 2 (3), 135, 2011 | 695 | 2011 |
| Targeting of cancer neoantigens with donor-derived T cell receptor repertoires E Strønen, M Toebes, S Kelderman, MM Van Buuren, W Yang, ... Science 352 (6291), 1337-1341, 2016 | 502 | 2016 |
| Effector CD4 and CD8 T cells and their role in the tumor microenvironment S Hadrup, M Donia, P Thor Straten Cancer Microenvironment 6, 123-133, 2013 | 413 | 2013 |
| Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma M Lauss, M Donia, K Harbst, R Andersen, S Mitra, F Rosengren, M Salim, ... Nature communications 8 (1), 1738, 2017 | 408 | 2017 |
| Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen R Andersen, M Donia, E Ellebaek, TH Borch, P Kongsted, TZ Iversen, ... Clinical cancer research 22 (15), 3734-3745, 2016 | 374 | 2016 |
| Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes AK Bentzen, AM Marquard, R Lyngaa, SK Saini, S Ramskov, M Donia, ... Nature biotechnology 34 (10), 1037-1045, 2016 | 353 | 2016 |
| Collagen density regulates the activity of tumor-infiltrating T cells DE Kuczek, AMH Larsen, ML Thorseth, M Carretta, A Kalvisa, ... Journal for immunotherapy of cancer 7, 1-15, 2019 | 343 | 2019 |
| Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy LS Steelman, RA Franklin, SL Abrams, W Chappell, CR Kempf, J Bäsecke, ... Leukemia 25 (7), 1080-1094, 2011 | 331 | 2011 |
| Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma MW Rohaan, TH Borch, JH Van Den Berg, Ö Met, R Kessels, ... New England journal of medicine 387 (23), 2113-2125, 2022 | 275 | 2022 |
| Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 MD Crowther, G Dolton, M Legut, ME Caillaud, A Lloyd, M Attaf, ... Nature immunology 21 (2), 178-185, 2020 | 256 | 2020 |
| Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway AM Martelli, C Evangelisti, W Chappell, SL Abrams, J Bäsecke, F Stivala, ... Leukemia 25 (7), 1064-1079, 2011 | 251 | 2011 |
| Principles of adoptive T cell therapy in cancer Ö Met, KM Jensen, CA Chamberlain, M Donia, IM Svane Seminars in immunopathology 41, 49-58, 2019 | 234 | 2019 |
| ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee U Keilholz, PA Ascierto, R Dummer, C Robert, P Lorigan, A Van Akkooi, ... Annals of oncology 31 (11), 1435-1448, 2020 | 200 | 2020 |
| Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients E Ellebaek, TZ Iversen, N Junker, M Donia, L Engell-Noerregaard, Ö Met, ... Journal of translational medicine 10, 1-12, 2012 | 195 | 2012 |
| Dissection of T-cell antigen specificity in human melanoma RS Andersen, CA Thrue, N Junker, R Lyngaa, M Donia, E Ellebæk, ... Cancer research 72 (7), 1642-1650, 2012 | 190 | 2012 |
| Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model H Jespersen, MF Lindberg, M Donia, EMV Söderberg, R Andersen, ... Nature communications 8 (1), 707, 2017 | 176 | 2017 |
| More tricks with tetramers: a practical guide to staining T cells with peptide–MHC multimers G Dolton, K Tungatt, A Lloyd, V Bianchi, SM Theaker, A Trimby, ... Immunology 146 (1), 11-22, 2015 | 164 | 2015 |
| Tumor-infiltrating lymphocytes for the treatment of metastatic cancer MHG Foppen, M Donia, IM Svane, J Haanen Molecular oncology 9 (10), 1918-1935, 2015 | 163 | 2015 |
Morten HansenNational Center for Cancer Immune Therapy at Copenhagen University HospitalVerified email at regionh.dk
